Fangchinoline protects against bone loss in OVX mice via inhibiting osteoclast formation, bone resorption and RANKL-induced signaling

Int J Biol Sci. 2020 Jan 1;16(2):309-319. doi: 10.7150/ijbs.37162. eCollection 2020.

Abstract

Osteoporosis is a disease characterized by abnormally increased formation and function of osteoclasts. Anti-RANKL treatment using natural medicine is a potential therapy for osteoporosis. Here, we studied the effect of fangchinoline, which is extracted from the root of Stephania tetrandra S. Moore, on osteoclast formation and function. We found that fangchinoline inhibited osteoclastogenesis at doses of 0.5 and 1 µM. In addition, we also examined the mechanism of the inhibitory effect of fangchinoline on osteoclasts. We found that fangchinoline down regulated NFATc1 activity and expression. However, fangchinoline did not affect IκBα degradation and MAPK pathways. In addition, we also found that fangchinoline could protect against bone loss in OVX mice. Taken together, fangchinoline may be a potential compound for osteoporosis.

Keywords: MAPK; NF-κB; NFATc1; RANKL; fangchinoline; osteoclast.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzylisoquinolines / pharmacology*
  • Blotting, Western
  • Bone Resorption / metabolism
  • Cell Differentiation / genetics
  • Cell Differentiation / physiology
  • Mice
  • NFATC Transcription Factors / genetics
  • NFATC Transcription Factors / metabolism
  • Osteoclasts / drug effects*
  • Osteoclasts / metabolism*
  • Osteogenesis / physiology
  • Ovariectomy
  • RAW 264.7 Cells
  • Signal Transduction / drug effects
  • Stephania tetrandra / chemistry

Substances

  • Benzylisoquinolines
  • NFATC Transcription Factors
  • fangchinoline